Investigation of the relationship between sensorineural hearing loss and associated comorbidities in patients with chronic kidney disease: A nationwide, population-based cohort study

Analysis of Auditory Function before and after a Single Session of Hemodialysis in Patients with Chronic Kidney Disease

Introduction  Hearing is a complex process that involves mechanical, chemical, and neurophysiological components. Changes in hearing can be caused by congenital or acquired etiological factors. Chronic kidney disease (CKD) is one of the causes of hearing loss. Objective  To compare auditory findings before and after a single session of hemodialysis in patients with chronic kidney disease. Methods  A clinical cross-sectional research was conducted with a sample of 23 individuals between 24 to 57 years of age with a diagnosis of CKD undergoing hemodialysis. Distortion product otoacoustic emission (DPOAE) and transient otoacoustic emission (TOAE) tests were performed before and after a session of hemodialysis. Results  The DPOAE test revealed that 26% of the participants had failure in both ears prior to dialysis and 30.4% had failure after dialysis. Comparing the DPOAE and TOAE tests before and after hemodialysis, a slight decrease was found in patients with "fail" results from the predialysis test to the postdialysis test, but the difference did not achieve statistical significance. Conclusions  No significant hearing changes assessed through otoacoustic emissions occurred after a single session of hemodialysis in the sample analyzed.

Low-dose Spironolactone Combined with ACEIs/ARBs May Reduce Cardiovascular Events in Patients with CKD Stages 3b-5: A Nationwide Population-Based Cohort Study in Taiwan

Background: ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly prescribed for hypertension and chronic kidney disease (CKD) management, but they can increase the risk of renal function deterioration and hyperkalaemia. Spironolactone, known for reducing cardiovascular events in CKD patients, faces limited use due to the risk of hyperkalaemia. This study evaluates the potential efficacy and complications of low-dose spironolactone as an adjunct therapy in patients with CKD stages 3b to 5 who are maintained on ACEIs or ARBs. Materials and methods: Hypertensive CKD patients (stages 3b-5) from Taiwan's National Health Insurance Research Database (2012-2016) were selected. Inverse probability treatment weighting (IPTW) was applied to balance baseline characteristics between patients treated with and without spironolactone. In this study, adherence to low-dose spironolactone (25 mg/day) was assessed using the medication possession ratio (MPR) over a continuous 3-month period within the first 12 months after initiation. Multivariate Cox regression models were used to compare clinical outcomes between two groups with MPR ≥80% and MPR <80%. The subgroup including poor adherence (MPR ≥40% and MPR <40%) was also evaluated. Results: Of the 2,623 advanced CKD patients on ACEIs/ARBs and spironolactone, 55.5% (n=1,456) had an MPR ≥80% over a median follow-up of 3.9 years. Post-IPTW, both groups were balanced. Patients with MPR ≥80% showed a lower risk of major adverse cardiovascular events (MACEs; aHR = 0.71, 95% CI = 0.57-0.89), nonfatal myocardial infarction (aHR = 0.54, 95% CI = 0.39-0.75), and heart failure hospitalization (aHR = 0.84, 95% CI = 0.72-0.98). No significant risk was observed for acute renal failure (aHR = 0.87, 95% CI = 0.75-1.02), chronic renal failure (aHR = 0.84, 95% CI = 0.71-1.00), or hyperkalaemia (aHR = 0.86, 95% CI = 0.69-1.07) in the MPR ≥80% group. Patients with MPR ≥40% also showed a lower risk of MACEs (aHR =0.78, 95% CI = 0.62-0.99) and nonfatal MI (aHR = 0.66, CI = 0.47-0.93). Conclusion: In Taiwan, higher adherence to low-dose spironolactone (25 mg/day) in ACEI/ARB-treated patients with CKD stages 3b-5 may reduce cardiovascular disease risk without increasing the risk of renal failure or hyperkalaemia.

A Systematic Review on Hearing and Balance in Patients with Chronic Kidney Disease with and Without Hemodialysis

Objective

Exploring the auditory and vestibular manifestations associated with chronic kidney disease (CKD) has been growing in recent years. Understanding these complaints in CKD patients is crucial for comprehensive patient care. This review aimed to investigate the audiological findings and profiles across various stages of CKD and guide for informed decision-making in their management.

Methods

Relevant articles from PubMed, ScienceDirect, EBSCO Medline, SCOPUS, Google Scholar, and Clinical Key were identified for review. The selected articles were published from 2008 to 2023 and written in English language. A total of 41 articles on auditory and vestibular assessments in CKD were eligible for review.

Results

Pure tone audiometry (PTA), immittance audiometry (IA) and otoacoustic emissions (OAEs) were the most commonly employed hearing tests respectively, with a higher frequency of utilization in hemodialysis cases compared to non-hemodialysis ones. Also, vestibular evoked myogenic potentials (VEMPs) emerged as the most popular vestibular test among hemodialysis patients while questionnaires were frequently employed in CKD patients. Moreover, our analysis suggests a potential association between the duration of hemodialysis and the development of tinnitus and vertigo. Abnormalities were also observed in auditory brainstem response (ABR), speech audiometry, central auditory processing tests and videonystagmography (VNG) assessment in hemodialysis and non-hemodialysis patients.

Conclusion

CKD patients, particularly those undergoing hemodialysis, face a higher risk of hearing loss, tinnitus, and vestibular complaints. Performing otoacoustic emissions and vestibular-evoked myogenic potentials along with PTA on CKD patients, regardless of the disease stage is recommended to more effective management of audiovestibular complaints in these population.

Association of intrinsic capacity and medication non-adherence among older adults with non-communicable diseases in Taiwan

OBJECTIVES

Medication non-adherence among older adults with non-communicable diseases (NCDs) remains prevalent worldwide, which causes hospitalization and mortality. Our study aimed to examine the association of medication non-adherence with level of overall intrinsic capacity (IC), pattern of IC, and specific IC component among older adults with NCDs.

METHODS

A cross-sectional questionnaire-based survey of 1268 older adults aged 60 years and above was conducted in 2022 in southern Taiwan. Among them, 894 suffered from 1 more NCD were included in this study. The Integrated Care for Older People Screening Tool for Taiwanese and the Adherence to Refills and Medication Scale were used to assess IC and medication non-adherence, respectively. Latent class analysis (LCA) was used to identify patterns of IC impairment, and binary logistic regression was used to assess the association between medication non-adherence and IC.

RESULTS

Older adults in the moderate (score: 1-2) or low (score≧3) overall IC groups were more likely to experience medication non-adherence (moderate: adjusted odds ratio (aOR) 1.57 [95% CI: 1.05-2.36]; low: 2.26 [1.40-3.67]). The "physical and nutritional impairments accompanied by depressive symptoms" group was associated with statistically higher odds of medication non-adherence (aOR 1.66 [1.01-2.73]). Older adults with cognitive impairment, hearing loss, or depressive symptoms showed greater likelihood of medication non-adherence (cognitive impairment: aOR 1.53 [1.03-2.27]; hearing loss: aOR 1.57 [1.03-2.37]; depressive symptoms: aOR 1.81 [1.17-2.80]).

CONCLUSIONS

Intervention for improving medication non-adherence among older adults with NCDs should consider IC.

The effectiveness of curcumin as a safe agent on hearing threshold improvement in patients with chronic kidney disease: a double-blind, placebo-controlled trial

Hearing impairment in patients with chronic kidney disease (CKD), can affect the quality of life. At present, hearing dysfunction does not have an approved pharmacologic therapy. This study aimed to investigate the protective effects and possible mechanisms of curcumin as a therapeutic agent on hearing impairment in patients with chronic kidney disease. We conducted a randomized controlled trial of 40 chronic kidney disease patients not on dialysis with hearing impairment. Participants were randomly divided into two groups. One group received curcumin daily and the other received a placebo for 12 weeks. The interval between III and V waves, latency of wave V, auditory brain stem response (ABR) threshold, speech reception threshold (SRT), and speech discrimination score (SDS) were evaluated and analyzed before and after the intervention. After treatment, in the curcumin group, III-V waves interval and the latency of wave V were significantly reduced (P value < 0.0001), also ABR threshold was demonstrated a significant improvement (P value < 0.0001). In the trial group, the SDS was increased (P = 0.001) and the SRT was attenuated (P < 0.0001). We had either significant deterioration due to the course of the disease or insignificant changes in the placebo group. Daily administration of curcumin, can significantly improve hearing impairment in CKD patients. Accordingly, curcumin should be considered as a therapeutic option for treating hearing impairment in patients with chronic kidney disease.

Association between hearing loss, tinnitus, and chronic kidney disease: the NHANES 2015-2018

Background

Previous studies suggested that chronic kidney disease (CKD) might contribute to hearing loss and tinnitus. Patients with CKD are often at risk of sudden onset hearing loss and tinnitus; however, few epidemiological investigations have been conducted on this topic. The purpose of this investigation was to analyze the correlation between hearing loss, tinnitus, and CKD based on information obtained from the National Health and Nutrition Examination Survey (NHANES).

Methods

Using data from the NHANES 2015-2018, a cross-sectional analysis was conducted, which included 5,131 participants, and used multivariate logistic regression analyses and subgroup analysis to investigate the association between hearing loss, tinnitus, and CKD.

Results

CKD was associated independently with hearing loss, with the CKD group being more at risk of hearing loss than the non-CKD group [age-adjusted 95% confidence interval (CI): 1.54 (1.31-1.8), p < 0.001]; multivariable-adjusted 95% CI: 1.31 (1.1-1.55), p = 0.002. Multifactorial logistic regression analysis did not find an association between CKD and tinnitus, however, further subgroup analyses showed a relationship in some populations.

Conclusion

The results suggested that CKD is associated with hearing loss and tinnitus. The complexity of the relationship between CKD and hearing loss requires further research.

The multifaceted links between hearing loss and chronic kidney disease

Hearing loss affects nearly 1.6 billion people and is the third-leading cause of disability worldwide. Chronic kidney disease (CKD) is also a common condition that is associated with adverse clinical outcomes and high health-care costs. From a developmental perspective, the structures responsible for hearing have a common morphogenetic origin with the kidney, and genetic abnormalities that cause familial forms of hearing loss can also lead to kidney disease. On a cellular level, normal kidney and cochlea function both depend on cilial activities at the apical surface, and kidney tubular cells and sensory epithelial cells of the inner ear use similar transport mechanisms to modify luminal fluid. The two organs also share the same collagen IV basement membrane network. Thus, strong developmental and physiological links exist between hearing and kidney function. These theoretical considerations are supported by epidemiological data demonstrating that CKD is associated with a graded and independent excess risk of sensorineural hearing loss. In addition to developmental and physiological links between kidney and cochlear function, hearing loss in patients with CKD may be driven by specific medications or treatments, including haemodialysis. The associations between these two common conditions are not commonly appreciated, yet have important implications for research and clinical practice.

Changes of FGF23 and hearing in chronic renal failure and their correlation analysis

BACKGROUND

To explore the association between fibroblast growth factor 23 (FGF23) and hearing in chronic renal failure (CRF).

METHODS

Pure tone audiometry was used to detect the hearing of patients with CRF; the level of serum FGF23, creatinine, blood urea nitrogen (BUN), parathyroid hormone (PTH), and mean binaural hearing threshold were compared to the control group (people without kidney disease). The rat model of renal failure was established by 5/6 nephrectomy, and the auditory brainstem response (ABR) of rats after modeling was detected by the Tucker Davis Technologies (TDT) system; the expression level of FGF23 in the peripheral blood, renal and cochlear tissue was also detected.

RESULTS

The incidence of hearing loss (HL) and serum FGF23 were higher in CRF patients than the control group; the sFGF23 was positively correlated with the mean binaural hearing threshold. Animal studies showed that the ABR threshold, creatinine, FGF23, BUN, and PTH increased after modeling; although, an increase in FGF23 was observed earlier than other indicators. The HL of rats with renal failure was significantly correlated with BUN, phosphate, PTH, sFGF23, kFGF23/β-actin, eFGF23/β-actin, weight, and modeling cycle.

CONCLUSIONS

Both CRF patients and rat models showed high-frequency HL. FGF23 was highly expressed in the serum of HL renal failure patients and rats, as well as in the renal tissue and cochlea of renal failure rats. Therefore, FGF23 may be involved in the occurrence and development of HL caused by CRF.

Systolic Blood Pressure and Objective Hearing Thresholds Among Japanese Middle-Aged Adults: A Facility-Based Retrospective Cohort Study

INTRODUCTION

Very few studies have compared the magnitude of the changes in the hearing thresholds at 1 and 4 kHz according to the systolic blood pressure (SBP). We investigated the effects of SBP on repeated measures of hearing threshold using pure-tone audiometry.

METHODS

This retrospective cohort study included 5,479 (for the analysis at 1 kHz) and 2,045 (for 4 kHz) individuals aged 50 to 59 years who underwent facility-based health checkups. A multivariable generalized linear mixed model was constructed for the analysis at 1 and 4 kHz.

RESULTS

The mean follow-up durations were 30,262 and 7,454 person-years, respectively. The interaction of SBP and year was significantly associated with the change in hearing threshold in both analyses at 1 kHz (with estimated slope, 0.00080; 95% confidence interval, 0.00049-0.00110) and 4 kHz (with estimated slope, 0.0042; 95% confidence interval, 0.0028-0.0057). The 10-year changes in hearing threshold with baseline SBP of 110 and 140 mm Hg were 0.4 and 0.6 dB at 1 kHz and 1.0 and 2.3 dB at 4 kHz, respectively.

CONCLUSIONS

Higher SBP was associated with an increased hearing threshold at both 1 and 4 kHz among middle-aged individuals.

Correlation study of FGF23/D-serine in maintenance hemodialysis patients with combined hearing impairment

BACKGROUND

Recent studies have reported an association between chronic renal failure and hearing impairment. Yet, the exact mechanism of action is still not fully understood. In this study, we investigated the expression of fibroblast growth factor 23 (FGF23) and D-serine in maintenance hemodialysis (MHD) patients with end-stage renal disease (ESRD) complicated with hearing impairment and further investigated the correlation between FGF23/D-serine and hearing impairment.

METHODS

A total of 90 subjects, including 30 MHD patients complicated with hearing impairment, 30 MHD patients with normal hearing, and 30 controls, were included in this case-control study. Relevant data were obtained by questionnaire survey, audiometric test, enzyme-linked immunosorbent assay (ELISA) to determine FGF23 level, and high-performance liquid chromatography to determine D-serine level.

RESULTS

MHD patients showed abnormally high expression of FGF23 and D-serine, where FGF23 and D-serine levels were significantly higher in the group with hearing impairment than in the group with normal hearing and normal controls (all P<0.01). Also, elevated FGF23 and D-serine were identified as risk factors for hearing impairment in ESRD, with ORs of 16.54 (95%CI, 2.75-99.55) and 15.22 (95%CI, 2.59-89.51), respectively. Further Person correlation analysis showed a moderate positive correlation between FGF23 and D-serine (r = 0.683, P<0.001).

CONCLUSION

This study provides potential biomarkers for the early detection of hearing impairment complicated by chronic renal failure, and the reduction of FGF23/D-serine may provide a potential target for the treatment of hearing impairment complicated by chronic renal failure.

Correlation between blood urea nitrogen level and cochlear outer hair cell function in non-dialysis chronic kidney disease patients

Background: Hearing loss due to impaired cochlear function, which results from increased blood urea nitrogen (BUN) level, is one of the important clinical problems in chronic kidney disease (CKD) patients with uremia. This study aims to determine correlation between blood urea nitrogen (BUN) levels and cochlear outer hair cell (OHC) dysfunction in non-dialysis stage 3-5 CKD patients so that the BUN levels may also be used to determine the presence of cochlear OHC dysfunction.

Design and methods: An observational analytic study with a cross sectional design and consecutive sampling. This study was conducted from November 2019 to February 2020 at the Department of Internal Medicine, Soetomo Hospital, Surabaya, Indonesia, and Otorhinolaryngology-Head and Neck Surgery Department, Soetomo Hospital, Surabaya, Indonesia. Non-dialysis CKD patients who met the inclusion and exclusion criteria were subjected to a Distortion Product Otoacoustic Emissions (DPOAE) test to assess cochlear OHC function at the Otorhinolaryngology- Head and Neck Surgery, Soetomo Hospital, Surabaya.

Results: Female patients were in larger number than male patients in a ratio of 1 : 2. Most of the patients were between 51-60 years of age. DPOAE distribution was refer in 25 patients (83.3%) and pass in 5 patients (16.7%). The highest pass was at 2000 Hz in 24 patients (80.0%), while the refer results were mostly at 12,000 Hz in 29 patients (96.7%). The highest average signal to noise ratio (SNR) was at 2000 Hz and 4000 Hz (12.77 dB and 11.13 dB), while the lowest at 11,000 Hz and 12,000 Hz (1.60 dB and 1.03 dB). Pearson’s correlation test on DPOAE results did not show a significant correlation (p>0.05) between BUN levels and impaired cochlear OHC function.

Conclusions: There was no correlation between increased blood urea nitrogen levels and cochlear outer hair cell function disorders in non-dialysis patients with CKD stage 3-5.

Association between kidney function and hearing impairment among middle-aged and elderly individuals: a cross-sectional population-based study

OBJECTIVE

As age-related diseases, chronic kidney disease and hearing impairment (HI) cause a serious socioeconomic burden. Due to structural similarities, there is a certain connection between kidney function and hearing, but there has been no large-scale epidemiological study in China that further explored this connection. Thus, this study aimed to explore the association between indicator levels of kidney function and hearing impairment among middle-aged and elderly individuals in Tianjin, China.

METHOD

In 2020, 1539 participants aged 45 years or older from Tianjin, China, were recruited into this study. All participants completed questionnaire surveys and underwent physical examinations, laboratory examinations, and hearing tests. The estimated glomerular filtration rate (eGFR) was calculated from serum creatinine (Cre) levels. HI was measured using pure-tone audiometry, and audiologists determined the final diagnoses.

RESULT

The prevalence of HI was 49.97%. With each 1-mL/min/1.73 m² increase in eGFR, the overall odds of HI increased by 1.3%; the risk increased by 2.4% and 1.6% for men and people aged 45-65 years, respectively. In contrast, in women, the odds of HI increased as Cre levels increased. Moreover, with each 1-mL/min/1.73 m² increase in eGFR, the overall odds of a one-degree increase in hearing loss increased by 1.7%; the odds increased by 2.3% and 1.5% for men and people aged 45-65 years, respectively. However, in women and people aged ≥65 years, the odds of a one-grade increase in hearing loss increased by 2.1% and 1.5%, respectively, with each 1-µmol/L increase in Cre. In addition, there were no significant relationships between blood urea nitrogen and hearing loss in multivariate analysis (all P > 0.05).

CONCLUSIONS

These findings suggest that eGFR and serum Cre are effective predictors of hearing loss. Thus, to decrease the burden of HI, hearing should be carefully monitored for people aged ≥45 years with elevated serum Cre and eGFR.

Correction: Investigation of the relationship between sensorineural hearing loss and associated comorbidities in patients with chronic kidney disease: A nationwide, population-based cohort study

[This corrects the article DOI: 10.1371/journal.pone.0238913.].